Follow real-time news, expert reporting, and comprehensive multi-source coverage about Startups.
Follow real-time news, expert reporting, and comprehensive multi-source coverage about Startups.

Eli Lilly announced it will acquire Merida Biosciences, a privately held biotech firm, in a deal valued at up to $2.875 billion. The transaction combines Lilly’s large‑scale drug development platform with Merida’s pipeline of antibody‑drug conjugates. Completion is expected later this year, subject to regulatory approval.